Compugen Ltd.
Uses AI to discover and develop novel antibody immunotherapies for hard-to-treat cancers.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Compugen Ltd. is a clinical-stage cancer immunotherapy company that specializes in the discovery and development of novel therapeutics. The company utilizes its proprietary computational discovery platform, Unigen™, which integrates artificial intelligence and machine learning (AI/ML) with deep scientific knowledge to identify novel drug targets. Compugen's primary focus is on developing first-in-class therapeutic antibodies and optimizing their combinations to treat cancer patients who are unresponsive or refractory to existing immunotherapies. A key area of its research involves the PVRIG pathway, a target the company discovered to enhance patient responses. Its pipeline consists of several therapeutic candidates currently being evaluated in multiple clinical trials.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-10-06 16:00 |
Regulatory News Service
Other Report or Announcement
|
English | 159.9 KB | ||
| 2025-10-06 16:00 |
Foreign Filer Report
Other Report or Announcement
|
English | 36.4 KB | ||
| 2025-09-17 16:00 |
Foreign Filer Report
RESULTS OF A MEETING HELD ON AUGUEST 6, 2025
|
English | 106.4 KB | ||
| 2025-09-17 16:00 |
Foreign Filer Report
RESULTS OF A MEETING HELD ON AUGUEST 6, 2025
|
English | 36.3 KB | ||
| 2025-09-08 16:00 |
Regulatory News Service
to Present Research at the Single Cell Genomics 2025 Conference
|
English | 94.0 KB | ||
| 2025-09-08 16:00 |
Foreign Filer Report
to Present Research at the Single Cell Genomics 2025 Conference
|
English | 36.5 KB | ||
| 2025-08-28 16:00 |
Regulatory News Service
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Confer…
|
English | 95.5 KB | ||
| 2025-08-28 16:00 |
Foreign Filer Report
Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Confer…
|
English | 36.4 KB | ||
| 2025-08-06 16:30 |
Foreign Filer Report
Immediate Report of Meeting to be held on September 16, 2025
|
English | 255.1 KB | ||
| 2025-08-06 16:30 |
Pre-Annual General Meeting Information
Immediate Report of Meeting to be held on September 16, 2025
|
English | 160.4 KB | ||
| 2025-08-06 16:00 |
Foreign Filer Report
Compugen Reports Second Quarter 2025 Results
|
English | 1.4 MB | ||
| 2025-08-06 16:00 |
Foreign Filer Report
Compugen Reports Second Quarter 2025 Results
|
English | 36.3 KB | ||
| 2025-07-28 16:00 |
Regulatory News Service
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resi…
|
English | 93.6 KB | ||
| 2025-07-28 16:00 |
Foreign Filer Report
Compugen to Present a Pooled Analysis of COM701 Phase 1 trials in Platinum Resi…
|
English | 36.5 KB | ||
| 2025-07-23 16:00 |
Report Publication Announcement
to Release Second Quarter 2025 Results on Wednesday, August 6, 2025, conference…
|
English | 91.0 KB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
